Cambrex President and CEO to be Honored by New York Law School
East Rutherford, NJ – Cambrex Corporation’s (NYSE: CBM, "Cambrex") President and CEO, Steven M. Klosk, will be honored by New York Law School on November 10th at the school’s 2010 Gala Celebration. Mr. Klosk and two others will be co-honored for uniquely personifying the core values of the school.
Mr. Klosk, a 1987 graduate of New York Law School’s evening division, will be awarded for both personally and professionally Embracing Innovation, a key focus of the school’s legal training.
Mr. Klosk joined Cambrex in 1992, and has held various executive positions including Chief Operating Officer, and was appointed President & CEO in 2008. Under Steve’s leadership, Cambrex has increased its focus on research and development in order to accelerate the number of novel products and services that Cambrex provides. The business has acquired or licensed access to several additional innovative technologies that are making Cambrex a leading provider of products and services to the pharmaceutical industry.
“I am honored to be recognized by New York Law School, and delighted to show my support to the school in appreciation of the outstanding education I received there. My experience at New York Law played a critical role in developing the foundation for my career in business. I was given the opportunity to be surrounded by very smart, very hardworking faculty and peers in an environment that fostered creative and analytical thinking. At Cambrex, creating value for our customers and the life sciences industry through technology and innovation is the key to growing in a highly competitive global market,” said Mr. Klosk.
Proceeds from the Gala celebration will be used to fund scholarships for talented law students and support the students and programming of the Diane Abbey Law Center for Children and Families. To learn more about the 2010 New York Law School Gala, please visit www.nyls.edu or call 212.431.2800.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.